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aged) surface and number of cells, the operator being still blinded
to the treatments.
Results: After three months of daily treatment, we observed that
the vehicle treated animals displayed severe OA with clefting and
erosion of the articular cartilage to the subchondral bone, with
prominent chondro-osseous metaplasias and often inﬂammation
and pannus. However, the OA grade of the tibial medial plateau
was signiﬁcantly decreased in the GS 400 group compared to
vehicle (median grade 2 vs. 5: Figure 1); when examining the OA
grade x stage, administration of both doses of GS was associated
with a signiﬁcant decrease from a median of 16 after vehicle, to
8 and 6 after GS 200 and 400, respectively (Figure 2). Histo-
morphometry showed that the rough surface/total surface ratio
Figure 1. OA grade.
Figure 2. OA grade x stage.
Figure 3. Rough surface/tot surface.
Figure 4. Ncells/volume.
was also decreased in both GS-treated groups compared to ve-
hicle (vehicle 0.79±0.05; GS 200 0.60±0.05; GS400 0.59±0.07,
p<0.05 vs. vehicle for both doses: Figure 3). Furthermore, the
number of viable chondrocytes within the matrix was signiﬁcantly
increased following treatment with GS at both doses (Figure 4).
Despite a similar positive trend, the effect of GS did not reach the
statistical signiﬁcance on the hystomorphometric assessment of
cartilage total volume and thickness.
Conclusions: GS changed the course of OA in the STR/Ort
mouse strain, by delaying cartilage breakdown as assessed his-
tologically and histomorphometrically. We conclude that GS ad-
ministration at human corresponding doses, reduced the severity
of the osteoarthritic pathology in a relevant mouse model.
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Purpose: Vitamin K (VK) has bone and cartilage effects. We
previously demonstrated an association between low VK levels
and radiographic osteoarthritis (ROA), osteophytes (OST), and
joint-space narrowing (JSN) in the hand and knee. However, to
evaluate whether VK might be of therapeutic beneﬁt in OA, a
trial is needed. As part of a RCT of VK supplementation, we
evaluated VK’s effect on hand OA, assuming OA in the hand
is more likely than OA in the knee to be affected by systemic
factors.
Methods: The OA study was ancillary to an ongoing NIH-funded
RCT assessing the effects of VK supplementation (500ug phyllo-
quinone/d vs placebo (PBO)) on bone loss and vascular calciﬁ-
cation among older adults who were not necessarily VK deﬁcient
at baseline (as measured by plasma phylloquinone). Both groups
received vitamin D (400IU) and calcium (600 mg) supplements.
At the ﬁnal 3-year study visit, bilateral hand PA x-rays were
obtained and read for features of OA by a board-certiﬁed MSK
radiologist. We assessed the effects of VK versus PBO on a per-
joint basis for ROA (K/L grade ≥2), JSN (grade ≥2), and OST
(grade ≥2) for all participants, and restricted post-hoc analysis
to the subgroup that had insufﬁcient VK concentrations (≤1nM
based on previous work) at baseline. We also compared the
effects of VK >1nM vs ≤1nM at the ﬁnal study visit in the
whole cohort and in the subgroup with insufﬁcient VK at base-
line. We conducted all analyses intention-to-treat using logistic
regression with GEE to adjust for correlation among joints within
an individual. Analyses were adjusted for age, sex, BMI, smok-
ing status, baseline 25(OH)-vitamin D, education, adherence to
supplements, and baseline physical activity.
Results: Of the 452 participants in the parent study, 378 con-
sented to this ancillary study. 193 were in the active treatment
arm (mean age 70.5 ± 5.5 yrs, 57.5% female, mean BMI 28.5
± 5.4 kg/m2, mean baseline VK 1.27 ± 1.76 nM) and 185 were
in the PBO arm (mean age 70.7 ± 5.5 yrs, 61.6% female, mean
BMI 27.6 ± 4.6 kg/m2, mean baseline VK 1.10 ± 1.40 nM).
There were no effects of randomization to VK for the ROA, JSN,
or OST outcomes (Table 1). In the subgroup that had insufﬁcient
VK at baseline, there were trends towards less radiographic OA
features, with those attaining sufﬁcient concentrations at the ﬁnal
study visit having 47% lower prevalence of JSN (p=0.02) and
22% lower prevalence of ROA (p=0.1).
Conclusions: In this 3-year RCT of VK supplementation in older
adults with and without VK deﬁciency, there was no overall
effect of VK on severity of radiographic hand OA. There was
a suggestion that those with insufﬁcient VK concentrations at
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Table 1
Adjusted* ORs (95% CI)
VK treatment VK levels >1nM vs ≤1nM
vs PBO at ﬁnal study visit
All Trial Subjects: (N=378)
ROA 1.03 (0.80-1.34) 0.96 (0.73-1.25)
P=0.8 P=0.7
OST 1.04 (0.68-1.57) 1.17 (0.74-1.85)
P=0.9 P=0.5
JSN 0.95 (0.64-1.40) 0.73 (0.49-1.10)
P=0.8 P=0.1
Subjects with VK ≤1nM at baseline: (N=221)
ROA 0.86 (0.62-1.19) 0.78 (0.56-1.07)
P=0.3 P=0.1
OST 0.87 (0.55-1.39) 0.88 (0.56-1.40)
P=0.6 P=0.5
JSN 0.83 (0.50-1.37) 0.53 (0.32-0.89)
P=0.5 P=0.02
*adjusted for age, sex, BMI, smoking status, baseline 25(OH)-vitamin D level,
educational level, adherence to supplements, and baseline physical activity as
measured by the PASE.
baseline, the group to whom therapy should be targeted, may
have had a beneﬁt, but there was inadequate power to address
this question deﬁnitively. This trial may not have been of long
enough duration or of sufﬁcient size to detect a true effect.
Treatment of VK deﬁciency which is common in elders may have
an as yet unproven favorable effect on disease.
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Purpose: To compare the systemic bioavailability of a new gel
formulation of diclofenac sodium 1% (DSG) when applied either
to 1 knee (normal use) or to 2 knees and 2 hands (maximal
exposure) to oral dosing with 50-mg diclofenac sodium enteric-
coated tablets in healthy age-matched volunteers representative
of the osteoarthritis (OA) population. The local tolerability of the
topical treatments was also assessed.
Methods: 40 Caucasians, 20 men and 20 women, of mean
age 59.9 years (range, 50 to 74) and mean BMI 26 kg/m2
(range, 20-33 kg/m2) were included in a single-center, open-
label, randomized, 3-way crossover study. Subjects received the
following three 7-day treatments in random order, separated by
14-day washout periods: A) 10 mg/cm2 i.e., 4 g gel applied qid
to 1 knee (total 16 g gel/day on surface area ∼400 cm2); B)
4 g gel qid per knee to both knees and 2 g gel qid per hand
applied to both hands (total 48 g gel/day on surface area ∼1200
cm2); and C) 50-mg tablets orally tid. Scheduled blood samples
were taken from Day 1 to Day 7 in each period. Cumulative urine
was collected over 24 h on Day 1 for Treatments A and B only
and over 24 h on Day 7 for all treatments. Pharmacokinetic (PK)
analysis included: concentration proﬁle of diclofenac in plasma
and derived AUC0-24 on Day 1 of treatment B; concentration
proﬁle of diclofenac in plasma at steady state and derived PK
parameters (Cmax, AUC0-24) on Day 7 for each treatment; amount
excreted into urine over 0 to 24 h (Ae0-24) for diclofenac and 4’-
OH-diclofenac (primary urinary metabolite) on Day 1 (treatments
A and B only) and on Day 7 for each treatment.
Results: 39 out of 40 subjects were included in the PK analysis.
Steady-state was reached by Day 7 for Treatments B and C, but
not for Treatment A. Diclofenac concentration peaked after each
administration of the oral treatment, but no obvious peak was
observed with the gel applications, and plasma concentration
over time was ﬂat (illustrated below in Figure 1).
Figure 1
The mean Cmax and AUC0-24 for treatment B (Cmax: 53.8 ± 32.0
ng/mL; AUC0-24: 807 ± 478 ngh/mL) were more than 3 times
those of treatment A (Cmax: 15.0 ± 7.33 ng/mL; AUC0-24: 233 ±
128 ngh/mL); these were both 1 or 2 orders of magnitude lower
than for treatment C (Cmax: 2270 ± 778 ng/mL; AUC0-24: 3890
± 1710 ngh/mL). Mean urinary excretion of diclofenac and its
major metabolite, 4’-OH-diclofenac, over 24 h was 3 to 4 times
higher for Treatment B than for Treatment A on Day 1 and 2 to
3 times higher on Day 7. Ratios of treatments on Day 7 and of
Day 7 to Day 1 for treatments A and B for the main bioavailability
parameters are provided below:
Ratios (N=39) Cmax AUC0-24 Ae0-24 diclo Ae0-24 4′-OH a
(%) (%) (%) (%)
Day 7
B/A 349 340 273 250
(302-403) (294-394) (224-332) (207-302)
A/C 0.633 5.79 2.51 2.21
(0.548-0.733) (5.00-6.70) (2.06-3.06) (1.82-2.68)b
A/C 0.633 5.79 2.51 2.21
B/C 2.21 19.7 6.85 5.52
(1.91-2.56) (17.0-22.8) (5.63-8.34) (4.56-6.69)b
Day 7/Day 1
A - - 493 666
(417-581) (561-790)
B - 417 285 402
(367-474) (248-327) (350-462)
a Primary urinary metabolite of diclofenac; b N=38.
Ten percent of subjects experienced mild local tolerability ad-
verse events (AEs) after topical Treatments A and B, while 8%
experienced mild gastrointestinal AEs after oral Treatment C.
General tolerability appeared better with topical Treatments A
and B (local reactions only) than with oral Treatment C.
Conclusions:Compared with oral diclofenac, systemic exposure
to diclofenac with topical DSG 1% ranged from 6% (17-fold lower)
for 1 knee to 20% for both hands and knees. DSG 1% was well
tolerated by the study population.
